Expertise in
5
conditions

Dr. Ari M. Vanderwalde

Oncology
7945 Wolf River Blvd, 
Germantown, TN 
Accepting New Patients
Offers Telehealth
Expertise in
5
conditions
7945 Wolf River Blvd, 
Germantown, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ari Vanderwalde is an Oncologist in Germantown, Tennessee. Dr. Vanderwalde is highly rated in 5 conditions, according to our data. His top areas of expertise are Melanoma, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Olfactory Neuroblastoma. Dr. Vanderwalde is currently accepting new patients.

His clinical research consists of co-authoring 72 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

7945 Wolf River Blvd, Germantown, TN 38138

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Biological
Study Drugs: RP1, Nivolumab
Study Phase: Phase 2
An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drug: Avelumab
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
View 4 Less Clinical Trials

72 Total Publications

Homologous Recombination Deficiency in Skin Cancers: Prevalence and Clinical Implications of This Distinct Patient Cohort.
Homologous Recombination Deficiency in Skin Cancers: Prevalence and Clinical Implications of This Distinct Patient Cohort.
Journal: JCO precision oncology
Published: January 14, 2026
Similar Doctors
Expertise in
26
conditions
Dr. Joseph Santoso
Oncology
Expertise in
26
conditions
Dr. Joseph Santoso
Oncology

Cardiology Specialists Of Memphis

80 Humphreys Center Dr Ste 202, 
Memphis, TN 
 (3.2 miles away)
901-226-4280
Languages Spoken:
English
See accepted insurances

Joseph Santoso is an Oncologist in Memphis, Tennessee. Dr. Santoso is highly rated in 26 conditions, according to our data. His top areas of expertise are Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, Ovarian Cancer, Hernia Surgery, and Hysterectomy.

Raymond Osarogiagbon
Expertise in
11
conditions
Dr. Raymond Osarogiagbon
Hematology Oncology | Hematology | Oncology
Expertise in
11
conditions
Dr. Raymond Osarogiagbon
Hematology Oncology | Hematology | Oncology

Laboratory Corporation Of America Holdings

7900 Airways Blvd Bldg B, 
Southaven,, MS 
 (15.1 miles away)
662-349-2442
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Raymond Osarogiagbon is a Hematologist Oncology specialist and a Hematologist in Southaven,, Mississippi. Dr. Osarogiagbon is highly rated in 11 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Nodules, Lung Adenocarcinoma, and Endoscopy.

Expertise in
9
conditions
Dr. Kenneth I. Ataga
Hematology Oncology | Hematology | Oncology
Expertise in
9
conditions
Dr. Kenneth I. Ataga
Hematology Oncology | Hematology | Oncology

UT Regional One Physicians Inc

890 Madison Ave, 
Memphis, TN 
 (13.3 miles away)
901-545-8999
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kenneth Ataga is a Hematologist Oncology specialist and a Hematologist in Memphis, Tennessee. Dr. Ataga is highly rated in 9 conditions, according to our data. His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia. Dr. Ataga is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vanderwalde's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile